Ariel Schwartz

Part of Absci Corp., Denovium, Inc. is an American artificial intelligence company that pioneers novel AI methods to accelerate innovation in biology. Denovium is building an artificial intelligence engine (Denovium EngineTM) capable of interpreting disparate biological data types to answer biology's toughest questions. The company partners with leading biotech and pharma companies in specific areas of focus, including gene discovery, protein engineering, and genomic medicine. The company was founded by Toby H. Richardson, Ariel Schwartz, Imad Ajjawi, and Gregory Hannum, with Toby H. Richardson serving as the CEO since incorporation. Denovium was acquired by Absci Corp. on January 12, 2021 for $4 million.

Part of Absci Corp., Denovium, Inc. is an American artificial intelligence company that pioneers novel AI methods to accelerate innovation in biology. Denovium is building an artificial intelligence engine (Denovium EngineTM) capable of interpreting disparate biological data types to answer biology's toughest questions. The company partners with leading biotech and pharma companies in specific areas of focus, including gene discovery, protein engineering, and genomic medicine. The company was founded by Toby H. Richardson, Ariel Schwartz, Imad Ajjawi, and Gregory Hannum, with Toby H. Richardson serving as the CEO since incorporation. Denovium was acquired by Absci Corp. on January 12, 2021 for $4 million.

Part of Absci Corp., Denovium, Inc. is an American artificial intelligence company that pioneers novel AI methods to accelerate innovation in biology. Denovium is building an artificial intelligence engine (Denovium EngineTM) capable of interpreting disparate biological data types to answer biology's toughest questions. The company partners with leading biotech and pharma companies in specific areas of focus, including gene discovery, protein engineering, and genomic medicine. The company was founded by Toby H. Richardson, Ariel Schwartz, Imad Ajjawi, and Gregory Hannum, with Toby H. Richardson serving as the CEO since incorporation. Denovium was acquired by Absci Corp. on January 12, 2021 for $4 million.